Principal Financial Group Inc ownership in 0TB / Theravance Biopharma, Inc.

Theravance Biopharma, Inc.

DE ˙ DB ˙ KYG8807B1068

13,90 € ↑0,30 (2,21%)

2026-06-05
DEL PRIS

Security	DE:0TB / Theravance Biopharma, Inc.
Institution	Principal Financial Group Inc
Latest Disclosed Ownership	52,264 shares
Latest Disclosed Value	$ 848,245

On May 4, 2026 - Principal Financial Group Inc filed a 13F-HR form disclosing ownership of 52,264 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $689,885 USD as of March 31, 2026. The entity filed a previous 13F-HR on July 29, 2024 disclosing 0 shares of Theravance Biopharma, Inc.. The current value of the position is $726,470 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-04	2026-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	52,264	52,264		848		0.0002
2024-07-29	2024-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	0	-14,708	-100.00	0	-100.00
2024-04-29	2024-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	14,708	-1,682	-10.26	132	-28.80	0.0001
2024-02-07	2023-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	16,390	-2,247	-12.06	184	15.00	0.0001
2023-11-02	2023-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	18,637	1,764	10.45	161	-8.05	0.0001
2023-08-07	2023-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	16,873	-570	-3.27	175	-7.94	0.0001
2023-05-09	2023-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	17,443	-1,112	-5.99	189	-9.13	0.0001
2023-02-09	2022-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	18,555	829	4.68	208	15.56	0.0002
2022-11-09	2022-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	17,726	52	0.29	180	12.50	0.0001
2022-08-10	2022-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	17,674	7,149	67.92	160	58.42	0.0001
2022-05-09	2022-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	10,525	10,525		101		0.0000
2022-02-09	2021-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	0	-24,799	-100.00	0	-100.00
2021-11-09	2021-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	24,799	9,949	67.00	184	-14.81	0.0001
2021-08-10	2021-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	14,850	740	5.24	216	-25.00	0.0001
2021-05-10	2021-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	14,110	-9,666	-40.65	288	-31.75	0.0002
2021-02-23	2020-12-31	13F/A-1	THERAVANCE BIOPHARMA	COM	G8807B106	23,776	12,222	105.78	422	146.78	0.0003
2021-02-08	2020-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	23,776	12,222		422		166.0213
2020-11-06	2020-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	11,554	-572	-4.72	171	-32.94	0.0001
2020-08-05	2020-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	12,126	3,486	40.35	255	27.50	0.0002
2020-05-12	2020-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	8,640	373	4.51	200	-6.54	0.0002
2020-02-05	2019-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	8,267	8,267		214		0.0002
2019-05-10	2019-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	0	-7,907	-100.00	0	-100.00
2019-02-14	2018-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	7,907	-6,725	-45.96	202	-57.74	0.0002
2018-11-14	2018-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	14,632	14,632		478		0.0004
2018-08-13	2018-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	0	-9,674	-100.00	0	-100.00
2018-05-14	2018-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	9,674	868	9.86	235	-4.47	0.0002
2018-02-12	2017-12-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	8,806	234	2.73	246	-16.33	0.0002
2017-11-02	2017-09-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	8,572	-5,757	-40.18	294	-48.51	0.0003
2017-08-08	2017-06-30	13F	THERAVANCE BIOPHARMA	COM	G8807B106	14,329	2,931	25.72	571	35.95	0.0006
2017-05-11	2017-03-31	13F	THERAVANCE BIOPHARMA	COM	G8807B106	11,398	11,398		420		0.0005

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.